FULC News

Nine companies entered the public market this week, led by customer experience software provider Medallia (MDLA) with a first day pop of 76%. The software company priced at $21, well above the range, to raise $326 million at a fully diluted valuation of $3.6 billion. Medallia’s growth accelerated to 32% in the most recent quarter, and it boasts 32...read more

Fulcrum Therapeutics, which is developing small molecule therapies based on gene regulation for rare diseases, raised $72 million by offering 4.5 million shares at $16, the low end of the range of $16 to $18. Fulcrum Therapeutics plans to list on the Nasdaq under the symbol FULC. Morgan Stanley, BofA Merrill Lynch and SVB Leerink acted as lead managers on the deal....read more

July's post-holiday flood of IPOs is upon us, with nine diverse offerings and a direct listing scheduled for the second-most active week of the year. The three largest IPOs come from Asia, Europe, and South America, but based on the strong reception of recent tech unicorns, Medallia (MDLA) may get the most eyeballs. DouYu (DOYU) is set to...read more

Fulcrum Therapeutics, a Phase 1 biotech developing therapies based on gene regulation for rare diseases, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $77 million by offering 4.5 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Fulcrum Therapeutics would command a fully diluted market value of $411...read more